gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AURAHealthcareBiotechnology

Aura Biosciences, Inc. Common Stock (AURA)

$6.50+4.09%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$6.24▲ 3.31% in range
Nov 3, 2025Low $4.97 · High $8.90Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Aura Biosciences closed at $6.50 on Nov 4, up 4.09%, 27.0% below its 52-week closing high. Volume of 373.6K shares was 0.43× its 20-day average (below normal).

Split-adjusted performance: +5.3% over one month, -21.7% over six months, +7.5% over one year.

Short interest was 10.9M shares at the Oct 15 settlement, up 5.0% from the prior report (11.8% of float, 10.6 days to cover).

Market cap$673.6M103.7M shares
Revenue · quarter$0.00—
Diluted EPS$-0.48—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range4.97 – 8.90−27.0% from high
Volume373.6K0.43× 20-day avg
Volatility · 60d41.0%Annualised
Short % of float11.8%10.6 days to cover
Net cash$323.8MCash $323.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.5%1M +5.3%3M −15.9%6M −21.7%YTD +19.2%1Y +7.5%3Y −13.1%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum48
Revenue growth—
Net margin—
Value (low P/E)—
Size65

Industry medians: 6-month return −19.5%, revenue growth +8.8%, net margin −312.9%, P/E 22.2×.

Short interest

Details →
Shares short10.9M+5.0% vs prior
Days to cover10.6Settled Oct 15
% of float11.8%
Short vol. 10d63.2%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AURAAura Biosciences$6.50+4.09%−21.7%———$673.6M
FDMT4D Molecular Therapeutics$12.18+1.92%+16.9%+25106.7%−1929.0%—$672.9MCompare
ATTOAttovia Therapeutics$14.97−1.96%————$683.4MCompare
CADLCandel Therapeutics$8.94+1.30%+17.1%———$683.7MCompare
SLDBSolid Biosciences$6.47+2.95%−10.2%———$693.2MCompare
DNAGinkgo Bioworks Holdings$11.15+3.58%+10.6%−48.5%−231.7%—$750.5MCompare
SANASana Biotechnology$2.59+5.94%−29.0%———$773.8MCompare
CGEMCullinan Therapeutics$12.44−21.05%−17.0%———$800.3MCompare
ENTXEntera Bio$3.14+2.95%+151.2%———$546.1MCompare

News about Aura Biosciences

All news →
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · May 19, 2026Neutral

Quick answers

What does Aura Biosciences do?
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer.
What is AURA's market cap?
$673.56M, based on the Nov 4 close of $6.50.
Does Aura Biosciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of AURA is sold short?
10.9M shares, 11.8% of float, as of Oct 15, 2026.
What sector is AURA in?
Healthcare, in the Biotechnology industry.

About Aura Biosciences

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

HQ: Boston, MA113 employeesListed Oct 29, 2021aurabiosciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology